Shares of GH Research PLC (GHRS) plummeted 22.4% in the pre-market session on Tuesday, as the Ireland-based biotech company commenced a $150 million stock offering to fund the development of its treatments for depression.
The sharp sell-off comes just one day after GHRS shares skyrocketed 70% to close at $17.99 on Monday, after the company announced that its depression therapy GH001 met the main goals of a mid-stage clinical study.
According to GH Research's SEC filing, the company plans to use the net proceeds from the stock sale to invest in research, clinical trials, and technical development of its current and additional product candidates targeting depression and other mental health disorders.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。